Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
Rhea-AI Summary
Bluejay Diagnostics (NASDAQ:BJDX) announced a strategic partnership with Argonaut Manufacturing Services to advance its Symphony™ near-patient diagnostic platform for critical care.
The collaboration focuses on building scalable U.S.-based manufacturing, strengthening commercial infrastructure, improving distribution and supply chain resilience, and reducing risks tied to overseas production and import tariffs.
AI-generated analysis. Not financial advice.
Positive
- U.S.-based partnership to support scalable manufacturing for the Symphony™ platform
- Collaboration aims to enhance U.S. product distribution and commercial infrastructure
- Initiative targets improved supply chain resilience and reduced import tariff exposure
- Domestic manufacturing expected to increase operational control and business continuity
Negative
- Symphony™ platform remains an investigational device, limited to investigational use under U.S. law
Market Reaction – BJDX
Following this news, BJDX has gained 11.98%, reflecting a significant positive market reaction. Argus tracked a peak move of +83.5% during the session. Our momentum scanner has triggered 19 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $2.43. This price movement has added approximately $240K to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves, with names like AEMD and NUWE appearing in momentum screens but splitting between gains and losses. With the target’s direction flag unset and peers not uniformly aligned, today’s action looks more company-specific than a clear sector-wide move.
Previous Partnership Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 09 | Symphony partnership expansion | Positive | +75.4% | Expanded manufacturing and commercialization support for Symphony platform with SanyoSeiko. |
Prior partnership news around the Symphony platform was followed by a strongly positive one-day move, suggesting investors have reacted favorably to commercialization and manufacturing collaborations.
Over the past several months, Bluejay has focused on advancing its Symphony near-patient diagnostic platform through clinical validation, manufacturing scale-up, and regulatory planning. A prior Oct 9, 2025 partnership with SanyoSeiko expanded manufacturing and supply-chain support for Symphony and was met with a strong positive share reaction of about 75.4%. Today’s Argonaut partnership continues this theme of building out manufacturing and commercialization infrastructure for Symphony-based critical care diagnostics.
Historical Comparison
In the past year, Bluejay had 1 prior partnership update on Symphony, which saw a 75.4% one-day move. Today’s Argonaut deal represents another step in the same commercialization track.
The company has moved from expanding its Symphony partnership with SanyoSeiko toward broader commercialization support to now adding Argonaut as a U.S.-based manufacturing and distribution partner, reinforcing the platform’s supply chain and launch readiness.
Regulatory & Risk Context
An active S-3 resale registration filed on 2025-10-23 covers up to 6,930,000 shares held by selling stockholders. The company itself is not selling shares under this registration and does not receive proceeds from resales, only from any warrant exercises for cash.
Market Pulse Summary
The stock is surging +12.0% following this news. A strong positive reaction aligns with the company’s history of sharp moves on partnership news; a prior Symphony collaboration produced a 75.4% one-day gain. However, filings highlight limited cash of $3.7 million and a need for about $20 million in additional capital by 2027, alongside an effective resale registration. These factors could influence how durable partnership-driven spikes ultimately prove.
Key Terms
investigational device regulatory
critical care medical
AI-generated analysis. Not financial advice.
ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testing for critical care, today announced a strategic partnership with Argonaut Manufacturing Services (“Argonaut”) to support the advancement of Bluejay’s Symphony™ platform.
This partnership is designed to support Bluejay’s broader efforts to establish scalable U.S.-based manufacturing capabilities aligned with its ongoing clinical development programs and future commercialization objectives. In addition, the partnership is intended to strengthen Bluejay’s future commercial infrastructure by supporting broader product distribution across the United States, enhancing supply chain resilience, and reducing potential risks associated with international sourcing and import tariffs. The collaboration is also intended to mitigate risks associated with Bluejay’s current reliance on overseas manufacturing by establishing domestic manufacturing capabilities that can provide greater operational control, business continuity, and supply chain security. By leveraging U.S.-based manufacturing and distribution capabilities, Bluejay aims to improve operational flexibility, support future market demand, and further enhance its ability to commercialize innovative near-patient diagnostic solutions for critical care settings.
“We are pleased to partner with Argonaut as we continue to advance the Symphony™ platform,” said Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics. “This collaboration reflects our commitment to building a scalable and quality-focused operational foundation as we progress toward key commercial milestones.”
“Argonaut is committed to partnering with innovative companies to support the advancement of differentiated diagnostic technologies,” said Rick Hancock, Chief Executive Officer of Argonaut Manufacturing Services. “We value this collaboration with Bluejay Diagnostics and look forward to supporting their efforts as they continue to develop solutions aimed at improving clinical decision-making in critical care settings.”
Note: Investigational device. Limited by United States law to investigational use.
About the SYMON Clinical Study Program:
The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to the FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
About Argonaut Manufacturing Services:
Argonaut Manufacturing Services is a contract manufacturing organization focused on supporting life sciences and diagnostics companies with high-quality manufacturing solutions. Founded by former executives from companies such as Thermo Fisher Scientific, Affymetrix, and Allergan, Argonaut was built to provide a better, customer-focused approach to contract manufacturing.
The company’s mission is centered on improving the human condition by helping partners bring innovative healthcare products to market efficiently and reliably. Drawing from decades of industry experience, Argonaut emphasizes quality, operational excellence, and strong customer collaboration to help clients achieve their commercial and development goals in the health and life sciences industries.
Forward-Looking Statements:
This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, “Risk Factors” in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
Website: www.bluejaydx.com
